BRIEF-EMA Starts Review For Use Of Imvanex Against Monkeypox

EMA: * EMA: MONKEYPOX: EMA STARTS REVIEW FOR IMVANEX: 28/06/2022

* EMA - CHMP HAS STARTED A REVIEW OF DATA TO EXTEND THE USE OF THE SMALLPOX VACCINE IMVANEX TO INCLUDE PROTECTING PEOPLE FROM MONKEYPOX DISEASE * EMA: EMERGENCY TASK FORCE (ETF) HAS RECOMMENDED THAT JYNNEOS CAN BE USED TO PROVIDE PROTECTION AGAINST MONKEYPOX DISEASE IN EU

* EMA - COMMONLY REPORTED SIDE EFFECTS WITH JYNNEOS ARE PAIN, REDNESS, SWELLING, ITCHING, HARDENING AT INJECTION SITE, MUSCLE PAIN, HEADACHE, AND FATIGUE * EMA - ETF NOTED USFDA'S CONCLUSION THAT EFFICACY OF JYNNEOS IN THE PREVENTION OF MONKEYPOX CAN BE INFERRED FROM ANTIBODY RESPONSES AGAINST VACCINIA VIRUS IN CLINICAL STUDIES

* EMA: TASK FORCE'S ADVICE TO SUPPORT NATIONAL AUTHORITIES WHO MAY DECIDE AS TEMPORARY MEASURE TO IMPORT JYNNEOS FROM US IN VIEW OF RISING RATES OF INFECTION * EMA - CHMP HAS STARTED A REVIEW OF DATA TO EXTEND THE USE OF THE SMALLPOX VACCINE IMVANEX TO INCLUDE PROTECTING PEOPLE FROM MONKEYPOX DISEASE Further company coverage: